On Tuesday, investment group Eurazeo announced that it had acquired a stake in Oncodesign Services, a company specializing in drug discovery and pre-clinical services in oncology and immuno-inflammation.

By investing €22 million via its Nov Santé Actions Non Cotées fund, Eurazeo will become a minority shareholder alongside the company's management and Edmond de Rothschild Private Equity.

In a press release, Eurazeo states that its investment has financed the acquisition of Dutch company ZoBio, specialized in preclinical small molecule research.

This first 'transforming' acquisition since the creation of Oncodesign Services aims to form a complete player in pre-clinical research services, with sales of 44 million euros and a workforce of almost 280 employees.

Oncodesign Services is the result of the separation, in 2022, of the Oncodesign group into two independent companies: a biotechnology entity called Oncodesign Precision Medicine, listed on the stock exchange, and a pre-clinical research services arm.

The latter offers a range of services from medicinal chemistry and pharmaco-imaging to molecular radiotherapy and in vitro and in vivo bio-analysis.

Eurazeo currently manages nearly 33.5 billion euros in diversified assets, including over 23 billion euros on behalf of third parties.

Copyright (c) 2024 CercleFinance.com. All rights reserved.